Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 3/20 | 0.41 |
| ▸ | CTSA | P10619 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL988863 | 0.81 | PTGDR2 (0.51) | AKR1C3AKR1C2PTGDR2ARPPARD | |
| SCHEMBL2770735 | 0.80 | PTGDR2 (0.48) | AKR1C3AKR1C2PTGDR2ARCYP1A2 | |
| SCHEMBL12948817 | 0.79 | PTGDR2 (0.45) | AKR1C3AKR1C2PTGDR2ARPPARD | |
| SCHEMBL1690237 | 0.71 | PTGDR2 (0.72) | PTGDR2CTSA | |
| SCHEMBL585016 | 0.70 | KDM4E (0.68) | PPARDPPARGPPARA | |
| SCHEMBL988515 | 0.69 | PTGDR2 (0.47) | PTGDR2AR | |
| SCHEMBL12147393 | 0.69 | PTGDR2 (0.72) | PTGDR2 | |
| SCHEMBL987439 | 0.69 | PTGDR2 (0.54) | AKR1C3AKR1C2PTGDR2PPARDPPARG | |
| SCHEMBL12296386 | 0.69 | PNMT (0.49) | — | |
| SCHEMBL10087246 | 0.69 | PNMT (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822467-B2 | Biaryl oxyacetic acid compounds | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2011002814-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010102154-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2010102154-A2 | BIARYL OXYACETIC ACID COMPOUNDS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102609-A1 | BIARYL OXYACETIC ACID COMPOUNDS | HSD17B12, CYP2A13, CYP27A1 | AKR1C3 16/4885AKR1C2 28/4885PTGDR2 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.